Objective: To explore the implementation status of China's centralized quantity purchasing policy for proprietary Chinese medicines and provide corresponding ideas for the sustainable development of the policy. Methods: By sorting out the current status of the policy implementation and based on the stakeholder perspective，it explored the effects of the policy implementation on health insurance departments，proprietary Chinese medicine companies，medical institutions and doctors and patients. Results: The implementation of the policy has consolidated the position of the health insurance sector in the pharmaceutical industry，effectively relieved of the pressure on the income and expenditure of the medical insurance fund，improved cost structure of proprietary Chinese medicine companies，increased industry concentration，reversed the revenue structure of medical institutions and physicians，reduced the financial burden of medication use for patients while the need for medication diversity has not been met. Conclusion: Setting a reasonable drug price range，continuously improving the income incentive mechanism for doctors in public hospitals，and adhering to the quality and safety as the core，to the needs of the people as the guide are still important directions for policy development.